跳至主要内容
临床试验/CTRI/2025/09/094365
CTRI/2025/09/094365招募中不适用

Effect of Diet and Exercise Intervention on Sarcopenic Obesity in Diabetic Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Prospective Interventional Study

Ritu Yadav1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2025年9月25日最近更新:

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
100
试验地点
1
主要终点
Improvement in sarcopenia and weight loss

研究概览

简要总结

Two groups will be made according to the inclusion and exclusion criteria

Group I (Control group) will be treated with a tailored dietary regime (a standard of care)

Group II (Study group) will be treated with a tailored dietary regime AND a tailored exercise regime

Interventions will be given for 24 weeks and follow-up will be taken till 52 weeks

The baseline data will be recorded and compared with intervention outcomes so that effect of Diet and Exercise Intervention can be measured in both groups

Data will be analyzed with an appropriate statistical tool.

研究设计

研究类型
Interventional
分配方式
Na
盲法
None

入排标准

年龄范围
19.00 Year(s) 至 70.00 Year(s)(—)
性别
All

入选标准

  • Diabetic patients who have sarcopenic obesity with metabolic dysfunction-associated steatotic liver disease (MASLD).
  • can provide written informed consent.

排除标准

  • Compensated and decompensated liver cirrhosis.
  • Large Esophageal Varices.
  • HCC or any other malignancy
  • Poor cardiopulmonary reserve or other advanced systemic disease (other than diabetes mellitus) with expected survival less than 1 year.
  • Patient on the Use of semaglutide T2DM drugs known to induce weight loss (GLP-1 agonists like semaglutide, GLP1-A +GIP-A like Trizepatide)
  • Organ failure.

结局指标

主要结局

Improvement in sarcopenia and weight loss

时间窗: 1 Year

次要结局

  • Proportion achieving(1. Improvement in sarcopenia)

研究者

发起方
Ritu Yadav
申办方类型
Other [self]
责任方
Principal Investigator
主要研究者

Ritu Yadav

Mahatma Gandhi University of Medical Science & Technology

研究点 (1)

Loading locations...

相似试验